EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

NCT03341494 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

128

Enrollment

OTHER_GOV

Sponsor class

Conditions

NSCLC Stage IV
Chemotherapy Effect

Interventions

DRUG: Thalidomide

Sponsor

Fujian Cancer Hospital